ArticleScientific reports2018
Targeting CD44v6 for fluorescence-guided surgery in head and neck squamous cell carcinoma.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 32 citations in OpenAlex.
- Targeting EpCAM expression via near-infrared fluorescent antibodies enables microscopic delineation of primary and recurrent HNSCC.BMC cancer · 2026Article
- Synthesis and preclinical evaluation of FAP-targeting radiotracers for PET and optical imaging.EJNMMI radiopharmacy and chemistry · 2025Article
- Evaluation of tumor targets selected from public genomic databases for imaging of pancreatic ductal adenocarcinoma.Scientific reports · 2025Article
- Dual-Nuclide Biodistribution and Therapeutic Evaluation of a Novel Antibody-Based Radiopharmaceutical in Anaplastic Thyroid Cancer Xenografts.Molecular cancer therapeutics · 2025Article
- CD44 and its implication in neoplastic diseases.MedComm · 2024Review
- CD44v6 specific CAR-NK cells for targeted immunotherapy of head and neck squamous cell carcinoma.Frontiers in immunology · 2023Article
- Advances in nuclear medicine-based molecular imaging in head and neck squamous cell carcinoma.Journal of translational medicine · 2022Review
- Targeted Dual-Modal PET/SPECT-NIR Imaging: From Building Blocks and Construction Strategies to Applications.Cancers · 2022Review
- Fundamentals and developments in fluorescence-guided cancer surgery.Nature reviews. Clinical oncology · 2022Review
- Integrin αvβ6 as a Target for Tumor-Specific Imaging of Vulvar Squamous Cell Carcinoma and Adjacent Premalignant Lesions.Cancers · 2021Article
- Current Intraoperative Imaging Techniques to Improve Surgical Resection of Laryngeal Cancer: A Systematic Review.Cancers · 2021Review
- Oral Cancer Stem Cells: Therapeutic Implications and Challenges.Frontiers in oral health · 2021Review
- Fluorescently Labeled Cetuximab-IRDye800 for Guided Surgical Excision of Ameloblastoma: A Proof of Principle Study.Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons · 2020Article
- Structural Characterization of the CD44 Stem Region for Standard and Cancer-Associated Isoforms.International journal of molecular sciences · 2020Article
- Cancer stem cells and oral cancer: insights into molecular mechanisms and therapeutic approaches.Cancer cell international · 2020Review
- Targeting cancer stem cells in squamous cell carcinoma.Precision clinical medicine · 2019Review
- Cancer Stem Cells in Head and Neck Squamous Cell Carcinoma: Identification, Characterization and Clinical Implications.Cancers · 2019Review
- New Developments in Dual-Labeled Molecular Imaging Agents.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019Review
- Emerging Fluorescent Molecular Tracers to Guide Intra-Operative Surgical Decision-Making.Frontiers in pharmacology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Head and neck squamous cell carcinoma (HNSCC) is an often highly invasive tumor, infiltrating functionally important tissue areas. Achieving complete tumor resection and preserving functionally relevant tissue structures depends on precise identification of tumor-free resection margins during surgery. Fluorescence-guided surgery (FGS), by intraoperative detection of tumor cells using a fluorescent tracer, may guide surgical excision and identify tumor-positive resection margins. Using a literature survey on potential surface molecules followed by immunohistochemical validation, we identified CD44 variant 6 (CD44v6) as a constitutively expressed antigen in the invasion zone of HNSCC lesions. The monoclonal anti-CD44v6 antibody BIWA was labeled with both a near-infrared fluorescent dye (IRDye800CW) and a radioactive label (Indium-111) and dual-modality imaging was applied in a locally invasive tumor mouse model. BIWA accurately detected human HNSCC xenografts in mice with a tumor uptake of 54 ± 11% ID/g and invasion regions with an accuracy of 94%. When dissected under clinical-like conditions, tumor remnants approximately 0.7 mm in diameter consisting of a few thousand cells were identified by fluorescence imaging, resulting in reliable dissection of invasive microregions. These data indicate that CD44v6 is a suitable target for reliable near-infrared detection and FGS of invasive HNSCC lesions in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.